Showing 61 - 71 of 71 reports matching: Metabolic Disorders
Journals
Specialties
Date of Publication
to
Synopsis: This meta-analysis included 9 studies comparing zoledronic acid and a placebo in patients with osteoporosis. Results from the analysis indicated that zoledronic acid was effective in increasing bone mineral density and reducing fracture rate. The zoledronic acid Read More »
Level 2 Meta Analysis
Synopsis: 50 patients with osteoporosis were randomized to receive traditional physical therapy or sling exercise therapy twice a week for 3 months. The results of Read More »
Level 2 RCT
Synopsis: 2679 post menopausal women with osteoporosis were randomly assigned to receive either an injection of a parathyroid hormone (PTH), or a placebo, to examine the safety and efficacy of a PTH injection. The results at 18 months, indicated that PTH was successful in reducing the risk for first fracture in those who had no prevalent fracture, as well as reducing additional fracture risk in women who had prevalent fractures. However, the findings Read More »
Level 2 RCT
Synopsis: 162 patients with Kashin-Beck disease (KBD) were randomized to evaluate the efficacy and tolerability of hyaluronic acid (HA) and meloxicam for the treatment of KBD related knee pain. Patients were assigned to either a 3-week course of HA or a 12-week course of meloxicam. When assessed over Read More »
Level 2 RCT
Synopsis: 4 randomised control trials were included in this meta-analysis, to compare the effectiveness of 60mg Denosumab subcutaneously per 6 months (Den) to 70mg Alendronate orally per week (Aln) in the treatment of osteoporosis in postmenopausal women. A total of 1952 women were identified that were followed-up for one year. The primary outcomes Read More »
Level 1 Meta Analysis
Synopsis: 242 male patients with low bone mineral density were randomized to receive treatment with denosumab or a placebo to determine the effect of denosumab on bone mineral density in the male population. After 1 year of treatment, the denosumab group demonstrated a significantly greater increase in bone mineral density than the control group at the lumbar spine, total hip, femoral neck, trochanter, and the one third radius. There was also Read More »
Author verified Level 2 RCT
Synopsis: 833 patients, undergoing treatment with glucocorticoids for 12 months, were randomized to receive zoledronic acid or risedronate in this double blind, double dummy trial. This study assessed the non-inferiority of one injection of zoledronic acid for the prevention and treatment of glucocorticoid induced osteoporosis compared to the daily oral risedronate dosage. Following the one Read More »
Author verified Level 1 RCT
Synopsis: 7868 women with osteoporosis, having a bone mineral density T score of less than -2.5 but no less than -4.0, were randomized to receive either injection with denosumab or an injection with placebo. Denosumab has been proposed to decrease bone resorption and thus improve bone mineral density in those patients with osteoporosis. This study aimed Read More »
Level 1 RCT
Synopsis: 4538 post-menopausal women (age 60-85) with low bone mineral density were randomized to either receive a daily dose of Tibolone (1.25mg) or an identical placebo. The results indicated that the use of tibolone resulted in a reduced risk for developing vertebral and non-vertebral fractures, invasive breast cancer as well as colon cancer. However, it is Read More »
Level 1 RCT
Synopsis: 184 osteopenic (T-score spine < -1.5) caucasian women all received daily administration of 1000 mg Ca and 20 microg cholecalciferol (Vit D3). In addition, the women were randomized to receive either oral choline-stabilized orthosilicic acid (ch-OSA) or placebo treatment for 1 year. 136 women completed the study. At 1 year, Read More »
Level 2 RCT
Synopsis: This network meta-analysis identified 6 Cochrane Collaboration systematic reviews, comprised in total of 31 studies. These reviews examined the safety and benefits of 6 biologics in patients with rheumatoid arthritis (abatacept, adalimumab, anakinra, etanercept, infliximab and rituximab). The primary outcomes Read More »
Level 1 Meta Analysis